Olaparib treatment reduced AR levels only in BRCA2-knockdown prostate cancer cells, indicating that 6-TG and olaparib regulate AR through different molecular mechanisms, the first being BRCA2-independent and the second BRCA2-dependent. The gene discussed is BRCA2; the disease is prostate cancer.